Syapse has entered into a strategic collaboration with Pfizer to advance cancer outcomes research using real-world evidence. The collaboration will initially focus on the molecular testing and therapy choices on precision oncology in the healthcare system setting.
 
“Pfizer is committed to using real-world evidence to improve cancer care and decision-making by healthcare providers,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “We look forward to working with Syapse and its network of health system partners to better understand the treatment journeys of people living with cancer and develop evidence-based insights that can help improve outcomes.”
 
“Pfizer is on the forefront of utilizing real-world data to improve the lives of patients worldwide and we are pleased to work with them to unlock evidence and insights that can help improve patient care and accelerate the availability of new treatments,” said Ken Tarkoff, CEO of Syapse. “To realize the potential of precision medicine all of the stakeholders in the healthcare ecosystem need to work together. At Syapse, we are proud of the collaborations we are facilitating between life science companies and health systems and we are committed to translating this work into solutions that help providers deliver consistent, cost-effective, patient-centered cancer care.”